Golestan University of Medical Sciences Repository

Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer

Abdollahpour-Alitappeh, M. and Lotfinia, M. and Bagheri, N. and Sineh Sepehr, K. and Habibi-Anbouhi, M. and Kobarfard, F. and Balalaie, S. and Foroumadi, A. and Abbaszadeh-Goudarzi, G. and Abbaszadeh-Goudarzi, K. and Abolhassani, M. (2019) Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer. Journal of Cellular Physiology, 234 (3). pp. 2693-2704.

Full text not available from this repository.


Targeted therapy using specific monoclonal antibodies (mAbs) conjugated to chemotherapeutic agents or toxins has become one of the top priorities in cancer therapy. Antibody�drug conjugates (ADCs) are emerging as a promising strategy for cancer-targeted therapy. In this study, trastuzumab, a humanized monoclonal anti-HER2 antibody, was reduced by dithiothreitol and conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) through a valine-citrulline peptide linker (trastuzumab-MC-Val-Cit-PABC-MMAE trastuzumab-vcMMAE). After conjugation, ADCs were characterized by using UV�vis, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and flow cytometry. The antitumor activity of the ADC was evaluated in breast cancer cells in vitro. In addition, ADCs were further characterized using purification by the protein A chromatography, followed by assessment using apoptosis and MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assays. Hydrophobic interaction chromatography was used to determine drug-to-antibody ratio species of ADCs produced. Our finding showed that approximately 5.12 drug molecules were conjugated to each mAb. H2L2, H2L, HL, H2, H, and L forms of ADCs were detected in nonreducing SDS-PAGE. The binding of trastuzumab-vcMMAE to HER2-positive cells was comparable with that of the parental mAb. The MTT assay showed that our ADCs induced significant cell death in HER2-positive cells, but not in HER2-negative cells. The ADCs produced was a mixture of species, unconjugated trastuzumab (14.147%), as well as trastuzumab conjugated with two (44.868%), four (16.886%), six (13.238%), and eight (10.861%) molecules of MMAE. These results indicated that MMAE-conjugated trastuzumab significantly increases the cytotoxic activity of trastuzumab, demonstrating high affinity, specificity, and antitumor activity in vitro. Trastuzumab-vcMMAE is an effective and selective agent for the treatment of HER2-positive breast tumors. © 2018 Wiley Periodicals, Inc.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: antibody drug conjugate; citrulline; dithiothreitol; monoclonal antibody; trastuzumab; valine; vedotin, antineoplastic activity; apoptosis; Article; controlled study; cytotoxicity; drug conjugation; drug potency; drug purification; drug selectivity; flow cytometry; human; human cell; human epidermal growth factor receptor 2 positive breast cancer; hydrophobic interaction chromatography; in vitro study; microtubule; polyacrylamide gel electrophoresis; priority journal
Subjects: بیماریهای زنان WP
QU بیوشیمی
فارماکولوژی QV
> دانشکده داروسازی > فارماکولوژی QV

آسیب شناسی QZ
مقالات نمایه شده محققین دانشگاه در سایت ,Web of Science ,Scopus
Divisions: معاونت تحقیقات و فناوری
Depositing User: GOUMS
Date Deposited: 01 Jul 2019 09:24
Last Modified: 01 Jul 2019 09:24
URI: http://eprints.goums.ac.ir/id/eprint/10251

Actions (login required)

View Item View Item